Dr Steven Knapper



Prosiectau fel Prif Ymchwiliwr
null null 1 o 6 null null

Evaluation of TAM receptor kinase inhibitor ONO-AX-280 in acute myeloid leukaemia (AML) - Cyllidwr:Ono Pharmaceuticals Laboratories Co Ltd (15.10.2014 - 30.11.2016)
Effect of CHr-2845 on AML M4/M5 primary patient isolates - Cyllidwr:Chroma Therapeutics Ltd (01.06.2012 - 31.05.2013)
Therapy Acceleration Programme (TAP) Clinical Centre - Cyllidwr:Blood Cancer UK (01.01.2012 - 31.12.2016)


Prosiectau fel Cyd-Ymchwiliwr
null null 1 o 2 null null


Diweddarwyd y tro diwethaf ar 2020-09-08 am 04:01